Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$471.85 USD

471.85
1,399,486

+1.77 (0.38%)

Updated Aug 11, 2025 04:00 PM ET

After-Market: $472.00 +0.15 (0.03%) 5:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Patterson Companies (PDCO) Misses Q1 Earnings Estimates

by Zacks Equity Research

Patterson Companies' (PDCO) adjusted earnings declines considerably on a year-over-year basis in Q1. Lackluster performance by the dental unit is a concern.

    Zacks Equity Research

    Here's Why You Should Buy Inogen (INGN) Stock Right Now

    by Zacks Equity Research

    Inogen (INGN) gains from strong Q2 results and bright global prospects.

      Zacks Equity Research

      Here's Why You Should Invest in Genomic Health (GHDX) Now

      by Zacks Equity Research

      Genomic Health (GHDX) gains ground on growing adoption of prostate cancer test and solid international scenario.

        Zacks Equity Research

        Ecolab's Nalco Pairs With XOS to Boost Global Energy Unit

        by Zacks Equity Research

        Ecolab's (ECL) Nalco Champion's 3D CRUDEFLEX will integrate XOS' Clora Online; market prospects bright.

          Zacks Equity Research

          New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales

          by Zacks Equity Research

          Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.

            Zacks Equity Research

            Phibro Animal (PAHC) Q4 Earnings Beat, Sales Improve Y/Y

            by Zacks Equity Research

            Phibro (PAHC) witnesses year-over-year improvement across all segments in Q4.

              Zacks Equity Research

              Wright Medical Buys Cartiva to Boost Lower Extremities Unit

              by Zacks Equity Research

              Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.

                Zacks Equity Research

                STERIS (STE) Strategic Growth Strong, Competition a Woe

                by Zacks Equity Research

                STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.

                  Zacks Equity Research

                  Bruker to Expand Molecular Diagnostics Arm With Hain Buyout

                  by Zacks Equity Research

                  Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.

                    Zacks Equity Research

                    Omnicell Patient Engagement Unit to Aid Medication Adherence

                    by Zacks Equity Research

                    Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.

                      Nalak Das headshot

                      Indexes Close at Record High as Markets Move North: 5 Picks

                      by Nalak Das

                      As a result of markets' northbound movement, two major indexes ??? S&P 500 and Nasdaq Composite ??? closed at an all-time high on Aug 24.

                        Zacks Equity Research

                        Hill-Rom (HRC) Touches 52-Week High: What's Driving It?

                        by Zacks Equity Research

                        Hill-Rom (HRC) rides high on impressive Q3 results along with increased focus on product innovation through research and development.

                          Zacks Equity Research

                          Veeva Systems (VEEV) Q2 Earnings & Revenues Beat Estimates

                          by Zacks Equity Research

                          Veeva Systems (VEEV) gains from its flagship Vault platform. Also, expanding margins are an added positive for the company.

                            Zacks Equity Research

                            Here's Why You Should Invest in Illumina (ILMN) Stock Now

                            by Zacks Equity Research

                            Illumina (ILMN) gains on strategic partnerships and international prospects.

                              Zacks Equity Research

                              Ecolab's New Aquanomic Enhances Laundry Operations at Hotels

                              by Zacks Equity Research

                              Ecolab's (ECL) new Aquanomic 2.0 Low-Temp Solid Laundry Program likely to boost Global Institutional segment.

                                Zacks Equity Research

                                Neogen's (NEOG) Listeria Right Now Gets Approval from AOAC

                                by Zacks Equity Research

                                Neogen's (NEOG) Listeria Right Now likely to prove beneficial in preventing food-borne diseases in the United States.

                                  Zacks Equity Research

                                  Masimo (MASI) Scales a 52-Week High: What's Driving It?

                                  by Zacks Equity Research

                                  Masimo's (MASI) solid guidance for 2018 and a broad product spectrum drive stock.

                                    Zacks Equity Research

                                    Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4

                                    by Zacks Equity Research

                                    Myriad Genetics (MYGN) witnesses strong performances from GeneSight, EndoPredict, Vectra DA and Prolaris tests in Q4.

                                      Zacks Equity Research

                                      Medtronic (MDT) Q1 Earnings Beat on Growth in All Lines

                                      by Zacks Equity Research

                                      All major business groups of Medtronic (MDT) contribute to solid top-line growth at CER, which highlighted sustainability across groups and regions.

                                        Zacks Equity Research

                                        Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                                        by Zacks Equity Research

                                        Amedisys (AMED) witnesses solid Medicare and non-Medicare revenues at Home Health and Hospice divisions. A favorable demographic trend bodes well.

                                          Zacks Equity Research

                                          Becton, Dickinson Hits at a 52-Week High: What's Driving It?

                                          by Zacks Equity Research

                                          Becton, Dickinson (BDX) gains on solid fiscal Q3 results; view impressive.

                                            Zacks Equity Research

                                            Will Strong RTG Arm Shape Medtronic's (MDT) Q1 Earnings?

                                            by Zacks Equity Research

                                            Medtronic (MDT) poised to gain on continued growth in RTG business in Q1.

                                              Zacks Equity Research

                                              Will Solid Diabetes Arm Drive Medtronic's (MDT) Q1 Earnings?

                                              by Zacks Equity Research

                                              Medtronic (MDT) poised to gain on strength in Diabetes business in Q1 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.

                                                Zacks Equity Research

                                                Haemonetics Strong on Plasma Unit Amid Blood Center Weakness

                                                by Zacks Equity Research

                                                Haemonetics (HAE) witnesses strong growth in Plasma franchise. Dullness in Blood Center business prevails.

                                                  Zacks Equity Research

                                                  Cardinal Health Product Spectrum Broad, Competition Rife

                                                  by Zacks Equity Research

                                                  Cardinal Health's (CAH) strategic buyouts lend it a competitive edge; the Cordis unit lacks luster.